H.C. Wainwright assumed coverage of Moleculin Biotech (MBRX) with a Buy rating and $4 price target Moleculin is a clinical-stage biotech company advancing treatments for highly resistant cancers and viruses, the analyst tells investors in a research note. The firm says the MIRACLE Part A data could position annamycin for accelerated approval in second-line acute myeloid leukemia.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech: Positive Clinical Trial Results and Strategic Developments Support Buy Rating
- Moleculin Biotech Hosts Key Opinion Leaders Event
- Moleculin Biotech releases KOL webcast to discuss Phase 1B/2 annamycin data
- Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories